EUVIMEDEUVIMED entdecken
Crossref

Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease

Tari G Michael, Moataz M Sayed, Hagar A El Essawy, Ahmed M F Mansour, Christine R Lotfy, Ahmed M El Ghandour

The Egyptian journal of Immunology · 2025

DOI: 10.55133/eji.320414 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Egyptian journal of Immunology, 2025. Verfasst von Tari G Michael und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Gastroenterology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Hauptthemen laut MEDLINE: Infliximab, Oncostatin M, Inflammatory Bowel Diseases, Colitis, Ulcerative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Crohn’s disease (CD) and ulcerative colitis (UC) are two types of inflammatory bowel diseases (IBD) diagnosed by chronic inflammation of the gastrointestinal system. Despite being the gold standard for assessing the therapeutic response to biological medicines like infliximab and disease activity in IBD patients, endoscopy's widespread use is limited by its time-consuming, expensive, and intrusive nature. This prospective case-control study was performed at Ain Shams University School of Medicine Hospital to examine the clinical utility of serum oncostatin M (OSM) as a biomarker for disease activity and response to infliximab in Egyptian IBD patients. It included 72 IBD patients (19 CD, 53 UC) and 29 controls. Patients were divided into three groups to investigate the connection between disease activity and OSM levels. To analyze the connection between OSM expression and clinical response, 36 IBD patients (22 with UC and 14 with CD) receiving infliximab maintenance were enrolled. All patients were subjected to comprehensive medical history, clinical evaluation, endoscopies, and detection of serum OSM levels. Of the 36 IBD patients, 18 patients responded to infliximab treatment, while the other 18 patients did not. The results demonstrated that, in comparison to controls, patients with IBD had higher levels of serum OSM expression. Serum OSM levels in IBD patients showed a positive association with disease activity. Individuals with moderate-to-severe UC and active CD had considerably elevated levels compared to those in remission. In conclusion, serum OSM showed as a promising biomarker for managing individuals with IBD, it was substantially expressed and positively connected with the severity of the disease. Infliximab non-response was linked to elevated OSM levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InfliximabOncostatin MInflammatory Bowel DiseasesColitis, UlcerativeCrohn DiseaseHumansMaleFemaleAdultBiomarkersCase-Control StudiesProspective StudiesMiddle AgedYoung AdultGastrointestinal AgentsTreatment Outcome

Substanzen

InfliximabOncostatin MBiomarkersGastrointestinal Agents

Autor:innen und Institutionen

  • Department of Internal Medicine and Gastroenterology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Zitieren

APA

Michael, T. G., Sayed, M. M., El Essawy, H. A., Mansour, A. M. F., Lotfy, C. R., & El Ghandour, A. M. (2025). Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease. The Egyptian journal of Immunology. https://doi.org/10.55133/eji.320414

Vancouver

Michael TG, Sayed MM, El Essawy HA, Mansour AMF, Lotfy CR, El Ghandour AM. Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease. The Egyptian journal of Immunology. 2025. doi:10.55133/eji.320414

BibTeX
@article{Michael2025,
  author = {Michael, Tari G and Sayed, Moataz M and El Essawy, Hagar A and Mansour, Ahmed M F and Lotfy, Christine R and El Ghandour, Ahmed M},
  title = {Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease},
  journal = {The Egyptian journal of Immunology},
  year = {2025},
  doi = {10.55133/eji.320414}
}
Kostenlos starten →